Article

Early outcomes favorable for epi-on CXL with iontophoresis

Results from 1 year of follow-up show that transepithelial corneal crosslinking (CXL) with iontophoresis appears to be safe and effective in arresting the progression of keratoconus, said Paolo Vinciguerra, MD.

Chicago-Results from 1 year of follow-up show that transepithelial corneal crosslinking (CXL) with iontophoresis appears to be safe and effective in arresting the progression of keratoconus, said Paolo Vinciguerra, MD.

Dr. Vinciguerra presented outcomes data from 20 eyes of 20 patients-all with documented progressive ectatic disease-during Refractive Subspecialty Day here at the annual meeting of the American Academy of Ophthalmology. The treated patients were 18 years of age and older and were seen at serial visits at 1, 3, 6, and 12 months, said Dr. Vinciguerra, of the ophthalmology department, Istituto Clinico Huanitas Rozzano, Milan, Italy.

In case you missed it: Research shows cure for posterior uveal melanoma not far from reach

Overall, the results showed significant improvement of best-corrected visual acuity accompanied by reductions in higher-order aberrations and average keratometry readings. Safety data showed that pachymetry measurements and endothelial cell counts were stable.

Complications included frequent epithelial defects and one case of epithelial burn.

 

 

“These results are promising in suggesting that transepithelial CXL with ionotphoresis has the potential to become a valid alternative for halting the progression of ectatic disease with benefits of reducing postoperative pain, infection risk, and treatment time compared with the standard epithelium-off technique,” Dr. Vinciguerra said. “However, we need longer follow-up. We have reported that a flattening effect is maintained at 5 years after epithelium-off CXL. Therefore, it will be important to wait for the results of the transepithelial iontophoresis procedure after 2, 3, 4, or more years.” 

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.